Experimental and Clinical Psychopharmacology
June 25, 2018
Lais Fernanda Berro, Hannah Shields, Melis Odabas-Geldiay et al.
6 citations
(-) MDMA (0.3, 1.0, or 1.7 mg/kg) at 9 or 16 h (3 h before "lights off"). Morning treatments had no effects on sleep-like parameters. Racemic MDMA decreased general daytime activity during the first hour after injection and increased daytime activity at 3 hr posttreatment. Although afternoon administration of racemic MDMA increased sleep latency, it improved other sleep parameters, decreasing...
The FASEB Journal
April 1, 2012
Kevin Sean Murnane, Leonard Lee Howell
The neuropharmacology of the sleep and arousal systems involves a complex interplay between multiple neurotransmitter systems. Previous work has downplayed the role of dopamine in sleep and wakefulness, at least in part, because dopamine neurons do not appear to change their firing rates across arousal states. In the present study, we examined the wake promoting effects of amphetamine and...
The FASEB Journal
April 1, 2012
Daniel Walker Curry, Kevin Sean Murnane, Leonard Lee Howell
The drug 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) has been shown to increase feelings of closeness and empathy in humans. Despite evidence of MDMA‐induced neurotoxicity, these unusual pro‐social effects have continued to generate interest in the drug's therapeutic potential. Therefore, determining the mechanisms by which MDMA engenders these effects may allow for the development of...
Psychopharmacology
April 2012
Kevin Sean Murnane, Shane Alan Perrine, Brendan James Finton et al.
Considerable evidence indicates that amphetamine derivatives can deplete brain monoaminergic neurotransmitters. However, the behavioral and cognitive consequences of neurochemical depletions induced by amphetamines are not well established. In this study, mice were exposed to dosing regimens of 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine (METH), or parachloroamphetamine (PCA)...